Genetic predisposition to lung cancer

Chest

Volumn 125, Issue 5 SUPPL., 2004, Pages 86S-89S

  Schwartz, Ann G ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE; MUTANT PROTEIN; MYELOPEROXIDASE; PROTEIN P53;

CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; DNA POLYMORPHISM; DNA REPAIR; FAMILIAL CANCER; GENE ACTIVITY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC PREDISPOSITION; HEREDITY; HUMAN; INHERITANCE; LUNG CARCINOGENESIS; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 2442543093     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.5_suppl.86S     Document Type: Conference Paper

References (30)

1. Reis LAG, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975-2000: National Cancer Institute. Available at: http://SEER.cancer. gov/csr/1975_2000. Accessed April 12, 2004
2. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health 1987; 77:425-431
3. Ooi WL, Elston RC, Chen VW, et al. Increased familial risk for lung cancer. J Natl Cancer Inst 1986; 76:217-222
4. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554-562
5. Mayne ST, Buenconsejo J, Janerich DT. Familial cancer history and lung cancer risk in United States nonsmoking men and women. Cancer Epidemiol Biomarkers Prev 1999; 8:1065-1069
6. Bromen K, Pohlabeln H, Jahn I, et al. Aggregation of lung cancer in families: results from a population-based case-control study in Germany. Am J Epidemiol 2000; 152:497-505
7. Sellers TA, Bailey-Wilson JE, Elston RC, et al. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 1990; 82:1272-1279
8. Yang P, Schwartz AG, McAllister AE, et al. Lung cancer risk in families of nonsmoking probands: heterogeneity by age at diagnosis. Genet Epidemiol 1999; 17:253-273
9. Yang P, Schwartz AG, McAllister A, et al. Genetic analysis of families with nonsmoking lung cancer probands. Genet Epidemiol 1997; 14:181-197
10. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasms. Science 1990; 250:1233-1238
11. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131-133
12. LeMarchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998; 58:4858-4863
13. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 2000; 10:105-114
14. 3801 C polymorphisms and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls. Int J Cancer 2003; 104:650-657
15. Houlston RS. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 1999; 8:675-682
16. Benhamou S, Lee WJ, Alexandrie A-K, et al. Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002; 23:1343-1350
17. Tailio E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003; 32:60-63
18. Ford JG, Li Y, O'Sullivan MM, et al. Glutathione S-transferase M1 polymorphism and lung cancer risk in African-Americans. Carcinogenesis 2000; 21:1971-1975
19. Quinones L, Lucas D, Godoy J, et al. CYP1A1, CYP2E1, and GSTM1 genetic polymorphisms: the effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 2001; 174:35-44
20. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992; 83:866-870
21. Alexandrie A-K, Sundberg MI, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15:1785-1790
22. Schabath M, Spitz M, Hong WK, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 2002; 37:35-40
23. -463G→ A polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:181-184
24. -463G→ A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:1550-1554
25. -463G→ A polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev 2002; 11:1555-1559
26. Wiencke JK, Spitz MR, McMillan A, et al. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997; 6:87-92
27. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H: quinone oxidoreductase 1 gene polymorphism and lung cancer, differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001; 303-309
28. Sunaga N, Kohno T, Yanagitani N, et al. Contribution of NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 2002; 11: 730-738
29. Chen H, Lum A, Seifried A, et al. Association of the NAD(P)H: quinone oxidoreductase 609C→ T polymorphism with a decreased lung cancer risk Cancer Res 1999; 59:3045-3048
30. Goode E, Ulrich CN, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:1513-1530